Genmab A (GMAB) Current Assets (2018 - 2026)
Genmab A's (GMAB) quarterly Current Assets came in at $2.6 billion in Q1 2026, down 36.26% YoY from $4.0 billion in Q1 2025, and down 10.81% on a QoQ basis from $2.9 billion in Q4 2025.
Genmab A (GMAB) Current Assets (2018 - 2026) Analysis & Trends
Genmab A (GMAB) has 7 years of Current Assets data on file, last reported at $2.6 billion in Q1 2026.
- Quarterly Current Assets fell 36.26% year-over-year to $2.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.6 billion (down 36.26% YoY) and the FY2025 annual result came in at $2.9 billion, down 26.03% from the prior year.
- Current Assets retreated to $2.6 billion in Q1 2026, from $2.9 billion in the prior quarter.
- In the past five years, Current Assets ranged from a high of $4.9 billion in Q4 2023 to a low of -$2.4 billion in Q3 2024.
- A 4-year average of $2.7 billion and a median of $3.9 billion in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2025 — Current Assets soared 1305.07% — and 2026, when it sank 36.26%.
- Tracing GMAB's Current Assets over 4 years: stood at $4.9 billion in 2023, then slipped by 20.6% to $3.9 billion in 2024, then dropped by 26.03% to $2.9 billion in 2025, then declined by 10.81% to $2.6 billion in 2026.
- The last three Current Assets figures came in at $2.6 billion (Q1 2026), $2.9 billion (Q4 2025), and $4.5 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | 2.80 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.80 Bn |
| Mar 31, 2026 | 2.57 Bn |
| Dec 31, 2025 | 2.89 Bn |
| Sep 30, 2025 | 4.47 Bn |
| Jun 30, 2025 | 3.91 Bn |
| Mar 31, 2025 | 4.04 Bn |
| Dec 31, 2024 | 3.90 Bn |
| Sep 30, 2024 | -2.40 Bn |
| Mar 31, 2024 | -335.00 Mn |
| Dec 31, 2023 | 4.91 Bn |
| Sep 30, 2020 | 19,504.00 |
| Dec 31, 2019 | 13,961.00 |
| Sep 30, 2019 | 12.26 Bn |
| Dec 31, 2018 | -831.75 Mn |